If you cannot read this message, click here.
     DDNews Top 5 Cancer Stories
       MARCH 2015
From our March 2015 issue:
MMRF and Inflection collaborate on new cancer treatment
By Jeffrey Bouley, DDNews Chief Editor
Current focus is on preclinical testing of innovative dual-mechanism PIM/PI3K inhibitor IBL-202

From our March 2015 issue:
Advancing NSCLC diagnosis and treatment
By Lloyd Dunlap, DDNews Managing Editor
Biocept and Insight Genetics team up to evaluate expression and mutation in ALK therapeutic target

From DDNews Online:
Eisai, Merck enter clinical trial collaboration
By Kelsey Kaustinen, DDNews Senior Editor
The companies will evaluate Merck's pembrolizumab in combination with two of Eisai's oncology compounds in a number of clinical trials

From DDNews Online:
Epizyme secures global rights to EZH2 program
By Kelsey Kaustinen, DDNews Senior Editor
Epizyme will make an upfront payment of $40 million to Eisai for the program rights, as well as up to $70 million in other milestone payments

From DDNews Online:
Bristol-Myers Squibb announces acquisition, collaboration
By Kelsey Kaustinen, DDNews Senior Editor
The company will acquire Flexus Biosciences for $1.25 billion, and will work with Rigel Pharmaceuticals to develop cancer immunotherapies
Facebook Facebook
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600 | Fax: 440-331-7563
©2015 Old River Publications LLC. All Rights Reserved.
Web site designed and managed by Offenberger & White, Inc..
If you no longer wish to receive DDNews mailings, please unsubscribe here.